|Bid||55.00 x 800|
|Ask||59.00 x 1200|
|Day's Range||55.01 - 56.01|
|52 Week Range||45.31 - 66.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.
Biotech stocks are breaking out, with the SPDR S&P Biotech ETF ( XBI) gearing up for what could be a significant rise higher. Since that time the group has turned higher, and now technical analysis suggests more gains may lie ahead for the sector.
Bothell's future as a thriving biotech hub hinges on its ability to compete with Seattle's Lake Union area. That's prompting changes that aim to make Bothell's business district a great place to work and play.
The company is the state's largest biotech, and has been growing quickly. Now, it's on the hunt for another building. Seattle Genetics is looking for a building that includes office and lab space. The company will likely remodel the new building.
On a per-share basis, the Bothell, Washington-based company said it had a loss of 73 cents. Losses, adjusted for non-recurring costs, were 61 cents per share. The results did not meet Wall Street expectations. ...
The Seattle-area’s largest biotech already has a footprint of about 500,000 square feet, which includes seven office buildings in Bothell, a manufacturing facility in North Creek and a Seattle office.
The biotech sector was in focus last week with Protagonist's stock plunging on news of discontinuation of a phase IIb study and Verona Pharma stock surging on positive top-line data from COPD study among others.
“This marks the first time in four decades and 10 different attempts to replace one of the most toxic drugs ... for late-stage classical Hodgkin while increasing long-term survival,” founder and CEO Clay Siegall said.
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
Seattle Genetics' (SGEN) cancer drug, Adcetris, gets FDA approval to include fifth indication, frontline treatment of advanced classical Hodgkin lymphoma, in its label.
U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, making it the first new treatment in over 40 years. The widely expected approval opens up a key market for Seattle Genetics, which expects the drug to bring in $1 billion in sales within the next few years. "We're 100 percent launch-ready," Chief Executive Clay Siegall said in an interview ahead of the decision.
Seattle Genetics Inc. has appointed Alpna Seth to its board of directors, expanding the board to nine people including two women. Seth’s more than 20 years of experience in health care and biotechnology will help Seattle Genetics continue to build out its growing pipeline of cancer drugs, which includes four applications of its flagship drug Adcetris. “Seattle Genetics is on the cusp of a significant inflection point in its transition into a global, multi-product oncology company,” Seth said in a news release.
Alpna Seth's appointment expands the Seattle biotech's board to nine people including two women. Seth is chief operating officer at San Francisco-based Vir Biotechnology and previously was a senior vice president at Cambridge, Mass.-based Biogen.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Seattle Genetics Inc (NASDAQ:SGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.